Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification

ABSTRACT

Introduction

New potential biomarkers to pre-intervention identification of a clinically significant prostate cancer (csPCa) will prevent overdiagnosis and overtreatment and limit quality of life impairment of PCa patients.

Areas covered

We have developed a comprehensive review focusing our research on the increasing knowledge of the role of SelectMDX® in csPCa detection. Areas identified as clinically relevant are the ability of SelectMDX® to predict csPCa in active surveillance setting, its predictive ability when combined with multiparametric MRI and the role of SelectMDX® in the landscape of urinary biomarkers.

Expert opinion

Several PCa biomarkers have been developed either alone or in combination with clinical variables to improve csPCa detection. SelectMDX® score includes genomic markers, age, PSA, prostate volume, and digital rectal examination. Several studies have shown consistency in the ability to improve detection of csPCa, avoidance of unnecessary prostate biopsies, helpful in decision-making for clinical benefit of PCa patients with future well designed, and impactful studies.

KEYWORDS:

• Select MDX®
• biomarker
• diagnosis
• magnetic resonance imaging
• clinically significant prostate cancer

Article highlights

• Improvement in clinically significant prostate cancer detection is still a challenge in the era of multiparametric magnetic resonance imaging and the use of urinary and blood biomarkers could be useful.

• Predictive models combining clinical, imaging, genomic variables such as SelectMDX® score can improve detection of clinically significant prostate cancer and reduce the biopsy related complications.

• The SelectMDX® sensitivity and specificity is consistent and when both SelectMDX® and multiparametric magnetic resonance imaging results were negative or both tests positive achieved the highest negative predictive values and positive predictive values.

• SelectMDX® can help in the decision to carry out prostate biopsy or to choose the appropriate therapeutic approach.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.